Immunotherapy with dendritic cells as a cancer treatment: Perspectives and therapeutic potential

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 7, Issue 3, 2013, Pages 226-232

  Aleixo, André A R ^a   Michelin, Márcia A ^a,b   Murta, Eddie F C ^a,c  

^a Federal University of the Triângulo Mineiro UFTM   (Brazil)

^b UFTM   (Brazil)

^c FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Cancer; Dendritic cells; Immune response; Immunotherapy; Therapeutic potential; Tumor

Indexed keywords

B7 ANTIGEN; BETA INTERFERON; CD11 ANTIGEN; CD18 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOCYANIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; MELATONIN; PROSTAGLANDIN E2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADHERENT CELL; ADVANCED CANCER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CHEMOSENSITIZATION; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROPORATION; ENDOCYTOSIS; HUMAN; IMMUNOREGULATION; LIVER CANCER; LIVER TUMOR; LUNG CARCINOMA; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PATENTS AS TOPIC; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84888113280     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/18722148113079990001     Document Type: Article

References (60)

1. Burnet, M. Cancer: A biological approach. I. The processes of control. Br Med J 1957; 1(5022):779-86.
2. Thomas, L. On immunosurveillance in human cancer. Yale J Biol Med 1982; 55(3-4):329-33.
3. Scharovsky OG, Matar P, Fluck MZ, Rico MJ, Rabinovich GA. From immune surveillance to tumor-immune escape: The story of an enemy with multiple strategies of resistance and counterattack. Inmunología 2006; 25(2):101-14.
4. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immnunol 2001; 167(12):7153-6.
5. Lehrnbecher T, Koehl U, Wittekindt B, Bochennek K, Tramsen L, Klingebiel T, et al. Changes in host defense induced by malignancies and antineoplastic treatment: Implication for immunotherapeutic strategies. Lancet Oncol 2008; 9(3):269-78.
6. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells - conductors of tumor immunity? Curr Opin Immunol 2002; 14(2):165-71.
7. Abbas AK, Lichtman AH, Pillai SHIV. Cellular and molecular immunology. 6th ed. Elsevier: Rio de Janeiro 2008.
8. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004; 199(1): 9-26.
9. Travers P, Walport M, Janeway CA. Janeway's immunobiology. 7th ed. Artmed: Porto Alegre 2010.
10. Bevan MJ. Interaction antigens detected by cytotoxic T cells with the major histocompatibility complex as modifier. Nature 1975; 256 (5516):419-21.
11. Guermonprez P, Saveanu L, Kleijmeer, M. Davoust J, Van endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003; 425(6956):397-402.
12. Onuchic AC, Chammas R. Cancer and the tumor microenvironment. Rev Med São Paulo 2010; 89(1): 21-31.
13. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN- _ and lymphocytis prevent primary tumour development and shape tumour in munogenecity. Nature 2001; 410(6832):1107-11.
14. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137(5):1142-62.
15. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12(4):265-77.
16. Steinman RM. Dendritic cells: Understanding immunogenicity. Eur J Immunol 2007;37 (Suppl 1):S53-60.
17. Neves AR. The effect of febrile temperature on the phenotype and function of dendritic cells derived from sanguinary monocytes. 2008. PhD Thesis, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil 2008.
18. Bharvaga A, Mishra D, Banerjee S, Mishra PK. Dendritic cell engineering for tumor immnutherapy: From biology to clinical translation. Immunotherapy 2012; 4 (7): 703-18.
19. Favali CBF. Human dendritic cells and leishmania amazonisis: The cellular and immunological aspect. 2007.143 f. Phd thesis, Institute for health Sciences, Federal University of Bahia, Bahia, Brazil, 2007.
20. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392 (6673):245-52.
21. Zou GM, Tam YK. Cytokines in the generation and maturation of dendritic cells: Recent advances. Eur Cytokine Netw 2002; 13(2): 186-99.
22. Lopez CB, Sesma AF, Sharon CSM, Jerome Schulman JL, Moran TM. A mouse model for immunization with ex vivo virus-infected dendritic cells. Cellular Immunol 2000; 206 (2):107-15.
23. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune response in vitro and in vivo. Proc Natl Acad Sci 1998; 95(16):9482-7.
24. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70 (6):706-15.
25. Banchereau J. The long arm of immune system. Sci Am 2002; 287(5):52-9.
26. Kah-Wai L, Jacek T, Jacek R. Dendritic cells heterogeneity and its role in cancer immunity. J Cancer Res Ther 2006; 2(2):35-40.
27. Weider E, Anderson MD. Dendritic Cells: A basic review. Inter Soc Cell Ther 2003: 2-6.
28. Shortman K, Naik SH. Steady-state and inflammatory dendriticcell development. Nat Rev Immunol 2007; 7(1):19-30.
29. Steinman RM., Banchereau, J Taking dendritic cells into medicine. Nature 2007; 449 (7161):419-26.
30. Cella M, Scheidegger D, Palmer-lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184(2):747-52.
31. Schwartz, RH. A cell culture model for T cell anergy. Science 1990; 248(4961):1349-56.
32. Banchereau J, Palucka K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immnol 2005; 5(4): 269-306.
33. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117(5):1195-203.
34. Alvarez D, Vollmann EH, Andrian UH. Mechanisms and consequences of dendritic cell migration. Immunity 2008; 29 (3):325-42.
35. Yong X, Xiao YF, Gang L, Ele B, Lü MH, Hu CJ, et al. Strategies for enhancing vaccine-induced CTL antitumor immune response. J Biomed Biotechnol 2012; 2012:605045.
36. Dhodapkar MV, Dhodapka R KM, Palucka AK. Interactions of tumor cells with dendritic cells: Balancing immunity and tolerance. Cell Death Differ 2008; 15(1):39-50.
37. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8 {alpha} + dendritic cells. J Exp Med 2011; 208(10):2005-16
38. Meidenbauer N, Andreesen R, Mackensen A. Dendritic cells for specific cancer immunotherapy. Biol Chem 2001; (4):507-20.
39. Palucka AK, Ueno H, Fay J, Banchereau J. Dendritic cells: A critical player in cancer therapy? J Immunother 2008; 31(9):793-805.
40. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186(8): 1213-21.
41. Schuler G, Steinman RM. Dendritic cells as adjuvants for immunemediated resistance to tumors. J Exp Med 1997; 186(8):1183-7.
42. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161(10): 5516-24.
43. Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2004; 53(12): 1111-8.
44. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, et al. HPV 16/18-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006; 100(3):409-78.
45. Rodrigues CM, Matias BF, Murta EF, Michelin MA. The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells. Clin Med Insights Oncol 2011; 5: 107-15.
46. Aly HA. Cancer therapy and vaccination. J Immuno Methods 2012; 382(1-2): 1-23.
47. Brink, J.A.T., Van Ham, S.M., Zwaginga, J.J. Maturation of dendritic cells. US20090297541 (2009).
48. Barbuto, J.A.M., Gonzalez, R.P. Process for obtaining dendritic cell vaccine and immunomodulator or product employing these dendritic cells. PI0504559-2A (2007).
49. Engleman, E.G., Levy, R., Hsu, F., Benike, C. Methods for in vivo T cell activation by antigen-pulsed dendritic cells. WO1995034638 (1995).
50. Yuetsu, T. Differentiation/cultivation method for dendritic cells. WO2012160702 (2012).
51. Murphy, G.P., Boynton, A.L., Tjoa, B.A. Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy. US20130017600 (2013).
52. Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 2005; 103(4):763-71.
53. Wang, P., Yang, L., Baltimore, D. Targeted gene delivery for dendritic cell vaccination. US8329162 (2012).
54. Fatho, M., Wesarg, E., Lennerz, V., Van Der Bruggen, P., Wölfel, T., Debo, S. Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients. US8349558 (2013).
55. Brossart P, Wirths S, Stuhler G, Volker L, Reichardt VL, Kanz L, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96(9):3102-8.
56. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 2003; 52(3):155-61.
57. Bystryn, J.C. Shed antigen vaccine with dendritic cells adjuvant. WO2004012685 (2004).
58. Zheng Z, Takahashi M, Narita M, Toba K, Liu A, Furukawa T, et al. Generation of dendritic cells from adherent cells of cord blood by culture with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha. J Hematother Stem Cell Res 2000; 9(4):453-64.
59. Liu LN, Shivakumar R, Allen C, Fratantoni JC. Delivery of whole tumor lysate into dendritic cells for cancer vaccination. Methods Mol Biol 2008; 423:139-53.
60. Kang, C., Jeon, M. Preparing method of dendritic cell for cancer immunotherapy. EP1565196 (2004).